Kazia April 2021 Licensing EVT801 Update
Kazia CEO, Dr James Garner discusses the in-licensing of EVT801 - a small-molecule inhibitor of VEGFR3 - from Evotec (FRA: EVT), a leading European drug discovery and development company.
Congratulations to Dr James Garner and the Kazia Team on this fabulous drug EVT801 in licencing acquisition and ongoing collaboration with Evotec.
This is now posted on the Kazia website.
Regards.
- Forums
- ASX - By Stock
- Ann: Kazia Corporate Presentation
Kazia April 2021 Licensing EVT801 UpdateKazia CEO, Dr James...
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity